TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8462533

Group type: EXPERIMENTAL
Intervention: Lignocaine 0.39 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine 0.5 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine 0.63 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine 0.79 mg kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lignocaine 1.0 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study: 2579877

Group type: COMPARATOR
Intervention: 0.5% dl-S-596
Number of subjects: 31

Group type: COMPARATOR
Intervention: 1% dl-carteolol
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Topical flurbiprofen (0.1%)
Number of subjects: 31
Study: 31251795

Group type: EXPERIMENTAL
Intervention: Minimally invasive chromosome screening (MICS) using blastocyst culture medium (BCM)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Trophectoderm (TE) biopsy
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: MICS‐Inst
Number of subjects: 62
Study: 30128853

Group type: EXPERIMENTAL
Intervention: L-menthol mouth rinse (0.01%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ice ingestion (1.25 g kg-1)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo-flavored non-calorific mouth rinse
Number of subjects: 10
Study: 26410392

Group type: EXPERIMENTAL
Intervention: Filtered sugarcane molasses concentrate (FMC) administered as an oral supplement before a meal, with varying doses (exact doses not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo syrup (test meal 1)
Number of subjects: 0
Study: 25001494

Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging activations in unaffected siblings
Number of subjects: 15

Group type: COMPARATOR
Intervention: Functional magnetic resonance imaging activations in healthy control subjects
Number of subjects: 15
Study: 22665534

Group type: COMPARATOR
Intervention: Ifosfamide, vincristine, and dactinomycin (IVA)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Six-drug combination (IVA plus carboplatin, epirubicin, and etoposide)
Number of subjects: 457
Study: 20502877

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 84

Group type: COMPARATOR
Intervention: TVT-Secur
Number of subjects: 84
Study: 17629089

Group type: EXPERIMENTAL
Intervention: lafutidine 10 mg
Number of subjects: 11

Group type: COMPARATOR
Intervention: famotidine 20 mg
Number of subjects: 11
Study: 16130870

Group type: EXPERIMENTAL
Intervention: Adper Single Bond (SB)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Adper Prompt (PLP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Excite (EXC)
Number of subjects: 25

Group type: COMPARATOR
Intervention: AdheSE (ADH)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: OptiBond Solo Plus (OPT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: OptiBond Solo Plus SE (OPTSE)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Prime&Bond NT (PBNT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Xeno III (XEN)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: One-Step Plus (OST)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Tyrian SPE (TYR)
Number of subjects: 25
Study: 12904140

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 0
Study: 9578178

Group type: EXPERIMENTAL
Intervention: Aspirin and dipyridamole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipyridamole alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipyridamole after coronary artery bypass grafting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dipyridamole in patients with occlusive peripheral vascular disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole in pharmacological stress testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dipyridamole combined with warfarin
Number of subjects: 0
Study: 8083636

Group type: EXPERIMENTAL
Intervention: PsH group (17%-30% pseudohomophones among nonwords)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPsH group (no pseudohomophones)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Double lexical decision paradigm
Number of subjects: 0
Study: 2682348

Group type: EXPERIMENTAL
Intervention: Dietary erucic acid therapy
Number of subjects: 12
Study: 123815

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Definitive physiotherapy
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Corset
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Analgesic tablets
Number of subjects: 456
Study: 30685546

Group type: EXPERIMENTAL
Intervention: ViSi Mobile (VM) continuous monitoring
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: HealthPatch (HP) continuous monitoring
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nurse measurements
Number of subjects: 60
Study: 28438584

Group type: EXPERIMENTAL
Intervention: Facilitator to improve clinician‐family communication in the ICU
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Training research staff to be supportive of families’ emotional needs and logistical knowledge about the ICU
Number of subjects: 28
Study: 25986648

Group type: EXPERIMENTAL
Intervention: Gantong Granules (high-dose, medium-dose, low-dose)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 23906760

Group type: EXPERIMENTAL
Intervention: Eye drops containing eledoisin and carnitine
Number of subjects: 40
Study: 22066244

Group type: EXPERIMENTAL
Intervention: vitaprost plus (rectal suppositories), one suppository before going to bed 2 days before surgery and for 8 days after TUR, total course lasted for 10 days.
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no vitaprost plus treatment).
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: vitaprost plus (rectal suppositories).
Number of subjects: 55
Study: 18590592

Group type: EXPERIMENTAL
Intervention: n-3-enriched pork
Number of subjects: 33

Group type: COMPARATOR
Intervention: Regular pork (control)
Number of subjects: 33
Study: 16484571

Group type: EXPERIMENTAL
Intervention: Amoxicillin and omeprazole for Helicobacter pylori infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Garlic supplement (aged garlic extract and steam-distilled garlic oil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin supplement (vitamins E and C and selenium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15340534

Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV) + intravenous immunoglobulin (IVIG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Prednisone, glucurone, luminal, Xiaoyanlidanpian (Control)
Number of subjects: 25
Study: 11142413

Group type: EXPERIMENTAL
Intervention: Piroxicam 7.5 mg/day
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 9771366

Group type: EXPERIMENTAL
Intervention: Buffered lignocaine with adrenaline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control local anaesthetic solution
Number of subjects: 40
Study: 7836713

Group type: EXPERIMENTAL
Intervention: Octreotide (100‐micrograms bolus with a 100‐micrograms/h infusion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3046465

Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.2 mg kg‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentazocine (0.5 mg kg‐1)
Number of subjects: 0
Study: 31062119

Group type: EXPERIMENTAL
Intervention: Maternal nut consumption during first pregnancy trimester (> 32 g/week)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Maternal nut consumption during pregnancy (first trimester)
Number of subjects: 2208

Group type: EXPERIMENTAL
Intervention: Maternal nut consumption during third pregnancy trimester
Number of subjects: 2208
Study: 29018896

Group type: EXPERIMENTAL
Intervention: HYP extract (900 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 26995368

Group type: EXPERIMENTAL
Intervention: β-blocker therapy
Number of subjects: 3470

Group type: COMPARATOR
Intervention: No β-blocker therapy
Number of subjects: 3470
Study: 25272653

Group type: EXPERIMENTAL
Intervention: Fluoxetine (10 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Soybean (100 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg) plus Soybean (100 mg)
Number of subjects: 40
Study: 22229483

Group type: EXPERIMENTAL
Intervention: Lay-facilitated angina management programme
Number of subjects: 142

Group type: COMPARATOR
Intervention: Advice from an angina nurse specialist
Number of subjects: 142
Study: 18701556

Group type: COMPARATOR
Intervention: Adalimumab 40 mg every other week (eow) for 24 weeks, then switched to open-label adalimumab 40 mg eow.
Number of subjects: 311
Study: 17642246

Group type: EXPERIMENTAL
Intervention: Biologic agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concomitant corticosteroids or NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduction of biologics
Number of subjects: 0
Study: 15229669

Group type: EXPERIMENTAL
Intervention: Treatment in a warm climate (Lanzarote)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Treatment in Norway (Control)
Number of subjects: 87
Study: 12395803

Group type: EXPERIMENTAL
Intervention: Folic acid 2.0 mg daily
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Folic acid 0.2 mg daily
Number of subjects: 723

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study: 10457878

Group type: EXPERIMENTAL
Intervention: Diltiazem (0.2 mg kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol (0.02 mg kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil (0.05 mg kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 7788574

Group type: COMPARATOR
Intervention: Double-blind oral challenge with food additives (monosodium glutamate, tartrazine, sulfites, erythrosine, paraoxybenzoate, sodium benzoate, lactose, aspirin, and annate) under placebo control
Number of subjects: 6

Group type: COMPARATOR
Intervention: Exclusion diets and elimination of contactants
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Circulating immune complexes (CICs)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: C-reactive protein positivity
Number of subjects: 6

Group type: COMPARATOR
Intervention: Skin-prick tests and patch tests
Number of subjects: 6
Study: 1972605

Group type: EXPERIMENTAL
Intervention: Ranitidine (histamine H2-receptor antagonist)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 7
Study: 417376

Group type: EXPERIMENTAL
Intervention: Ethchlorvynol 500 mg for 14 days
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ethchlorvynol 500 mg
Number of subjects: 4
Study: 7136838

Group type: EXPERIMENTAL
Intervention: Implosive, counselling and conditioning approaches
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study: 31122856

Group type: EXPERIMENTAL
Intervention: PHiD‐CV10 vaccine
Number of subjects: 30527

Group type: COMPARATOR
Intervention: Hepatitis B vaccine (control)
Number of subjects: 30527
Study: 28651303

Group type: EXPERIMENTAL
Intervention: Nomogram for overall survival (OS) prediction
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Nomogram for recurrence-free survival
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Validation of nomogram
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Calibration curve
Number of subjects: 538
Study: 25602633

Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 64

Group type: COMPARATOR
Intervention: Gas (C 3 F 8) tamponade
Number of subjects: 64
Study: 24517082

Group type: EXPERIMENTAL
Intervention: Hydrocodone extended release (20-100 mg every 12 hours)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Hydrocodone extended release
Number of subjects: 510
Study: 23190512

Group type: EXPERIMENTAL
Intervention: High Hb group receiving darbepoetin alfa
Number of subjects: 321

Group type: COMPARATOR
Intervention: Low Hb group receiving epoetin alfa
Number of subjects: 321
Study: 19238909

Group type: EXPERIMENTAL
Intervention: Kremezin (K)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Merckmezin (M)
Number of subjects: 22
Study: 17628691

Group type: EXPERIMENTAL
Intervention: rppTMS (repetitive paired pulse TMS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 5 Hz rTMS (repetitive transcranial magnetic stimulation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham TMS
Number of subjects: 10
Study: 14981223

Group type: COMPARATOR
Intervention: Weight Watchers
Number of subjects: 48

Group type: COMPARATOR
Intervention: Individualized
Number of subjects: 48

Group type: COMPARATOR
Intervention: Comprehensive
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control
Number of subjects: 48
Study: 11844887

Group type: EXPERIMENTAL
Intervention: 5 mg olanzapine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 10 mg olanzapine
Number of subjects: 29

Group type: COMPARATOR
Intervention: 15 mg olanzapine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 5 mg or 10 mg olanzapine
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 29
Study: 10087078

Group type: EXPERIMENTAL
Intervention: Eye pursuit task
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Eye-finger pursuit task
Number of subjects: 6

Group type: COMPARATOR
Intervention: Eye fixation task
Number of subjects: 6
Study: 8528469

Group type: EXPERIMENTAL
Intervention: Discrimination of roughness
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Discrimination of length
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Somatosensory reaction time task
Number of subjects: 20
Study: 2260873

Group type: EXPERIMENTAL
Intervention: Endocrine therapy (adreno‐oophorectomy, H)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chemotherapy (FAC, C)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (FAC + tamoxifen, H'C)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Chemoendocrine therapy (FAC + adreno‐oophorectomy, HC)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (H)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 114
Study: 435016

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 50
Study: 31814511

Group type: EXPERIMENTAL
Intervention: Tailored CRC screening promotion intervention (phone counseling-only group)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Tailored CRC screening promotion intervention
Number of subjects: 603
Study: 30242948

Group type: EXPERIMENTAL
Intervention: liraglutide 0.6 mg daily, titrated to 1.2 mg after the first week
Number of subjects: 62

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: liraglutide
Number of subjects: 62
Study: 28591244

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk beverage (150 mL for 60 days)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-probiotic milk (150 mL for 60 days)
Number of subjects: 49
Study: 25728042

Group type: EXPERIMENTAL
Intervention: PBS skills training and personalized feedback (PBS-STPF) intervention
Number of subjects: 251

Group type: COMPARATOR
Intervention: Health-related control condition
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Both conditions (PBS-STPF and control)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: PBS-STPF intervention
Number of subjects: 251
Study: 24084800

Group type: EXPERIMENTAL
Intervention: Usual obstetric care and osteopathic manual treatment (UOBC+OMT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual obstetric care and sham ultrasound therapy (UOBC+SUT)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual obstetric care (UOBC)
Number of subjects: 144
Study: 21315807

Group type: EXPERIMENTAL
Intervention: Nicotine gum (6 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 24
Study: 18851771

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy for psychosis (CBTp)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 94
Study: 16778608

Group type: EXPERIMENTAL
Intervention: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 4 mL/sec
Number of subjects: 130

Group type: COMPARATOR
Intervention: 2 mL/kg of bw of a nonionic contrast agent (300 mg I/mL) injected at 3 mL/sec
Number of subjects: 130
Study: 14534763

Group type: EXPERIMENTAL
Intervention: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given before day 5 of illness
Number of subjects: 81

Group type: COMPARATOR
Intervention: Immunoglobulin (2 g/kg) and aspirin (80-100 mg/kg/day) given on or after day 5 of illness
Number of subjects: 81
Study: 12374709

Group type: EXPERIMENTAL
Intervention: TSA with 20 mL of 1.5% lidocaine (TSA-Lido)
Number of subjects: 12

Group type: COMPARATOR
Intervention: i.v. infusion with 300 mg of lidocaine (i.v.-Lido)
Number of subjects: 12
Study: 10215748

Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1000 mg every 8h
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral trimethoprim 200 mg once daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both drugs concomitantly
Number of subjects: 12
Study: 8642904

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atropine (0.03 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atenolol (10 mg)
Number of subjects: 10
Study: 2338194

Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg, twice a day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid, 10 mg/kg per day
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of lovastatin and ursodeoxycholic acid
Number of subjects: 9
Study: 459472

Group type: EXPERIMENTAL
Intervention: Isometric exercise after dehydration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotonic exercise after dehydration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isometric exercise after rehydration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Isotonic exercise after rehydration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control levels (predehydration)
Number of subjects: 20
Study: 29959787

Group type: EXPERIMENTAL
Intervention: Elobixibat 2.5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elobixibat 5 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elobixibat 10 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elobixibat 15 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Elobixibat 20 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26378033

Group type: EXPERIMENTAL
Intervention: Imatinib (200 mg daily)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 i.v. weekly × 4 doses, repeatable after 3 months)
Number of subjects: 72
Study: 25454967

Group type: EXPERIMENTAL
Intervention: Acupoint pressure therapy (APT)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Collateral meridian therapy (CMT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 49
Study: 22484079

Group type: EXPERIMENTAL
Intervention: Contextual cues in cued recall tasks
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Contextual cues in recognition tasks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cued recall
Number of subjects: 76

Group type: COMPARATOR
Intervention: Recognition memory
Number of subjects: 76
Study: 20569776

Group type: EXPERIMENTAL
Intervention: Unassisted bibliotherapy (n=20) with a scheduled follow‐up telephone interview, no therapist contact, treatment phase lasted for 10 weeks.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list control group (n=19).
Number of subjects: 39
Study: 18723851

Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration during head-up tilt test (HUT)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Head-up tilt test without nitroglycerin administration
Number of subjects: 97

Group type: COMPARATOR
Intervention: Head-up tilt test before nitrate administration
Number of subjects: 97
Study: 15709995

Group type: EXPERIMENTAL
Intervention: Beidellitic montmorillonite (3 g, t.d. for 8 weeks)
Number of subjects: 524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 524
Study: 11799340

Group type: EXPERIMENTAL
Intervention: Risperidone (0.5 to 6.0 mg/day, median dose 2.5 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 48
Study: 10525747

Group type: EXPERIMENTAL
Intervention: High magnitude voucher condition ($3480)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Low magnitude voucher condition ($382)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Zero magnitude voucher condition ($0)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All conditions (zero, low, high magnitude)
Number of subjects: 29
Study: 8735684

Group type: EXPERIMENTAL
Intervention: Oramorph SR (OSR)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: MST Continus (MST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 24

Group type: COMPARATOR
Intervention: Fed condition
Number of subjects: 24
Study: 1654987

Group type: EXPERIMENTAL
Intervention: 60 Gy radiotherapy (30 fractions over 6 weeks)
Number of subjects: 474

Group type: COMPARATOR
Intervention: 45 Gy radiotherapy (20 fractions over 4 weeks)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Prognostic index from previous MRC study
Number of subjects: 474
Study: 7065555

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 30252681

Group type: EXPERIMENTAL
Intervention: Colon J-pouch (CJP)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Side-to-end anastomosis (SEA)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Straight colorectal anastomosis (SCA)
Number of subjects: 336
Study: 30032816

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 419

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 419